Drugs such as Ozempic, Wegovy, and Mounjaro, which contain semaglutide and tirzepatide, have transformed the clinical management of diabetes and obesity globally. Semaglutide is considered one of the most effective treatment options for obesity, a condition affecting approximately 5% of Americans. However, these medications are associated with adverse effects including nausea, vomiting, severe abdominal pain, and in some cases, stomach paralysis. Additionally, Ozempic has been linked to serious eye conditions. The Pharmacy and Poisons Board has issued warnings against using Ozempic and similar weight loss drugs without a prescription, emphasizing that Ozempic is intended for treating Type 2 diabetes. Clinical trials such as the REDEFINE 1 phase 3a trial have confirmed semaglutide's weight-loss benefits, with cagrilintide showing promise in early studies when combined with semaglutide. Meanwhile, oral GLP-1 receptor agonists face challenges with patient adherence due to greater gastrointestinal side effects compared to injectable forms. There is also emerging concern about placebo dropout rates in obesity trials, potentially influenced by patient perceptions shaped by social media and media coverage. Separately, sodium-glucose cotransporter-2 (SGLT-2) inhibitors may soon be offered as first-line treatments for all diabetes patients, expanding beyond those with heart disease.